About the founders
ExpediteBio was founded by Richard van Rijnsoever and Debby Vermeer to redefine how biologics reach the clinic. Combining deep scientific expertise with strategic and operational leadership, they set out to eliminate the inefficiencies that slow early development and delay patient impact.
With a combined track record spanning early drug discovery, translational biology, cell line and process development, CMC strategy, clinical manufacturing, venture building, commercial and biotech operations, Debby and Richard share a common vision:
a smarter, parallelized development model that reduces time, cost, and risk for emerging therapeutics.
Their complementary backgrounds enable ExpediteBio to blend scientific rigor with executional excellence, supporting companies from initial concept through Phase 0/I-ready manufacturing. This holistic perspective ensures that programs advance efficiently, with disciplined decision-making and a clear line of sight to clinical validation.
Together, they lead a team dedicated to making high-quality, Phase 0/I-ready biologics accessible faster, strengthening innovation, improving capital efficiency, and helping Europe retain both scientific and economic value in the life sciences.
co-founder
Richard van Rijnsoever
Richard brings a strong commercial, operational, and strategic lens to the life sciences sector, shaped by experience in early-stage venture creation, technology development, CDMO leadership, and C-level business roles.
He is recognized for translating scientific innovation into scalable, market-ready opportunities and for driving commercial strategy and partnerships within CDMO environments. At ExpediteBio, Richard guides company strategy and growth, enabling faster and more capital-efficient progression from discovery to clinical validation.
co-founder
Debby Vermeer-Kruijsen, Ph.D
With deep expertise spanning early drug discovery, translational biology, cell line and process development, and operational leadership, Debby has guided multidisciplinary teams and complex partnerships to advance biologics from concept toward clinical readiness.
Recognized for her strategic insight and alliance leadership, she brings a decisive, execution‑driven approach that strengthens program momentum and organizational impact. At ExpediteBio, Debby leads strategic operations and high‑value partnerships, ensuring emerging therapeutics progress with speed and confidence.